Dr. Reddy’s Laboratories reported better-than-expected second-quarter results for fiscal 2027, driven by key product launches in the US. The company is targeting improved profit margins through its core portfolio, though upcoming USFDA inspections at key manufacturing facilities remain a factor for investors to monitor.
Dr. Reddy’s Laboratories recently reported a strong financial performance for the second quarter of fiscal 2027, with both operating profit and net profit figures surpassing analyst estimates by 32% and 26% respectively. This growth was largely supported by the company’s performance in the US market, where revenue increased by 9.5% sequentially to USD 258 million. The success in the US was attributed to the strategic launches of products like sugammadex and bosutnib, which helped the company achieve gross margins of 51.7%, the highest level seen since the loss of exclusivity for gRevlimid.
The company is now focusing on sustaining this momentum by targeting a 25% EBITDA margin over the next two years. This goal is expected to be supported by the expansion of its non-gRevlimid portfolio and a steady improvement in core business operations. For investors, the company has highlighted several upcoming growth triggers. These include the planned relaunch of semaglutide in November 2026 and the anticipated USFDA approval of the biosimilar abatacept in December 2026. These developments are seen as key steps in the company’s transition toward higher-value, complex generic and biosimilar products, which typically offer better profit margins than standard generic drugs.
While the outlook remains focused on growth, there are operational factors that investors should keep in mind. The approval for the abatacept biosimilar is contingent upon the successful completion of inspection activities at the company’s Bachupally manufacturing facility. Regulatory inspections by the USFDA are a standard yet critical process for pharmaceutical companies; any delay or adverse observation during these inspections can impact the launch timelines of new drugs and, consequently, affect revenue growth. Managing manufacturing compliance remains a vital operational priority for the company as it scales its presence in the US market.
In the broader pharmaceutical sector, companies are increasingly shifting their focus toward complex generics and specialty products to mitigate the intense price competition seen in standard oral solids. Dr. Reddy’s strategy appears to align with this industry-wide trend of seeking better margins through niche product launches. The key monitorables for investors moving forward will be the status of the upcoming USFDA inspections, the successful execution of the scheduled product launches in late 2026, and the company's ability to maintain its targeted EBITDA margins in a competitive global environment.